Skip to content
Loading your account…

PFE PFIZER INC

NYSEHealth carePharmaceutical PreparationsNew York, NYFY ends December 31

New 8-K: Filed an 8-K current report in the last 7 days.Profitable 5/5: Fiscal years with net income above zero, out of the last five reported.FY2025 10-K filed Feb 26, 2026 (SEC EDGAR)

FY2025 at a glance

Fundamentals from SEC filings, not quotes
Revenue
$62.6BYoYdown 1.65%ended Dec 31, 2025
Net income
$7.77B12.4% margin
Diluted EPS
$1.36YoYdown 3.55%
Free cash flow
$9.08B14.5% margin
Cash
$1.14BNet debt $63.5B
Total debt
$64.6BD/E 0.75×
About PFIZER INC

Overview

PFIZER INC (PFE) is listed on NYSE; the SEC classifies it under "Pharmaceutical Preparations".

For fiscal 2025 (ended Dec 31, 2025) it reported revenue of $62.58B, down 1.6% from fiscal 2024.

Net income was $7.77B, a net margin of 12.4%.

At fiscal year end it had total assets of $208.16B and stockholders' equity of $86.48B (41.5% of assets).

Fiscal years shown
FY2016–FY2025 (10 years)
Latest 10-K
Feb 26, 2026
Latest filing
8-KNov 3, 2026
FY2016–FY2025 · annual 10-K

Charts

Revenue and net income

Revenue and net income, fiscal years FY2016 to FY2025.
PeriodRevenueNet incomeNet margin
FY2016—$7.22B—
FY2017—$21.3B—
FY2018$53.6B$11.2B20.8%
FY2019$51.8B$16.3B31.4%
FY2020$41.9B$9.62B22.9%
FY2021$81.3B$22B27.0%
FY2022$100B$31.4B31.3%
FY2023$58.5B$2.12B3.6%
FY2024$63.6B$8.03B12.6%
FY2025$62.6B$7.77B12.4%

Gross, operating and net margin

Gross, operating and net margin, fiscal years FY2016 to FY2025.
PeriodGross marginNet margin
FY2016——
FY2017——
FY201879.0%20.8%
FY201980.3%31.4%
FY202079.3%22.9%
FY202162.1%27.0%
FY202265.8%31.3%
FY202357.3%3.6%
FY202471.9%12.6%
FY202574.3%12.4%

Diluted EPS

Diluted EPS, fiscal years FY2016 to FY2025.
PeriodEPS (diluted)
FY2016$1.17
FY2017$3.52
FY2018$1.87
FY2019$2.87
FY2020$1.71
FY2021$3.85
FY2022$5.47
FY2023$0.37
FY2024$1.41
FY2025$1.36

Free cash flow vs net income

Free cash flow vs net income, fiscal years FY2016 to FY2025.
PeriodFree cash flowNet income
FY2016$14.1B$7.22B
FY2017$14.5B$21.3B
FY2018$13.8B$11.2B
FY2019$10.4B$16.3B
FY2020$12.2B$9.62B
FY2021$29.9B$22B
FY2022$26B$31.4B
FY2023$4.79B$2.12B
FY2024$9.84B$8.03B
FY2025$9.08B$7.77B

Diluted shares

Diluted shares, fiscal years FY2016 to FY2025.
PeriodDiluted shares (weighted)
FY20166.16B
FY20176.06B
FY20185.98B
FY20195.68B
FY20205.63B
FY20215.71B
FY20225.73B
FY20235.71B
FY20245.7B
FY20255.71B

Cash vs total debt

Cash vs total debt, fiscal years FY2016 to FY2025.
PeriodCash & equivalentsTotal debt
FY2016$2.6B$35.6B
FY2017$1.34B$43.2B
FY2018$1.14B$40.8B
FY2019$1.31B$51.3B
FY2020$1.78B$39.7B
FY2021$1.94B$37.8B
FY2022$416M$35.4B
FY2023$2.85B$71.8B
FY2024$1.04B$63.6B
FY2025$1.14B$64.6B

Each bar is one fiscal year as reported in its 10-K; bars below the zero line are negative and gaps are years not reported. Per-share figures are as reported, not adjusted for stock splits; comparisons across a likely split are left blank.

FY2025 · 5-year trend

Ratios

Profitability

Gross margin
74.3%
Net margin
12.4%
FCF margin
14.5%
Return on equity
8.9%
Return on assets
3.7%

Growth

Growth. Compound annual growth: (end ÷ start)^(1 ÷ years) − 1, both ends positive.
Metric1y3y CAGR5y CAGR9y CAGR
Revenuedown 1.65%down 14.56%——
EPS (diluted)down 3.55%down 37.12%down 4.48%up 1.69%
Free cash flowdown 7.73%down 29.62%down 5.67%down 4.76%
Change in share count
+0.23%

Financial strength

Current ratio
1.16×
Debt / equity
0.75×
Liabilities / assets
58.3%
Net debt
$63.5B
Equity / assets
41.5%

Shareholder returns

Dividends per share
$1.72
Buybacks
—
Stock comp. / revenue
1.3%
Piotroski F-Score · Altman Z''-Score

Quality screens

Piotroski F-Score

6 of 9 checks passed

FY2025 vs FY2024

  • PassPositive return on assets3.6%
  • PassPositive operating cash flow$11.7B
  • PassReturn on assets improved3.6% vs 3.5%
  • PassOperating cash flow above net income5.5% vs 3.6%
  • FailLong-term debt / assets fell29.6% vs 26.9%
  • FailCurrent ratio improved1.16× vs 1.17×
  • FailNo increase in share count5.71B vs 5.7B
  • PassGross margin improved74.3% vs 71.9%
  • PassAsset turnover improved0.29× vs 0.28×

Altman Z''-Score

Needs current assets and liabilities, retained earnings, operating income, total assets, liabilities and equity from the latest 10-K.

Screening heuristic, not a recommendation. Per-share figures are as reported, not adjusted for stock splits; comparisons across a likely split are left blank.

Last 10 fiscal years · newest first

Financial statements

USD millions, except per-share figures (USD). Share counts in millions.

Income statement

Income statement. USD millions, except per-share figures (USD). Share counts in millions.
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023FY2022Dec 31, 2022FY2021Dec 31, 2021FY2020Dec 31, 2020FY2019Dec 31, 2019FY2018Dec 31, 2018FY2017Dec 31, 2017FY2016Dec 31, 2016
Revenue62,57963,62758,496100,33081,28841,90851,75053,647——
YoY (Revenue)-1.65%+8.77%-41.70%—+93.97%-19.02%-3.54%———
Gross profit46,51245,77633,54265,98650,46733,21641,53142,399——
Selling, general & admin.13,79414,73014,77113,67712,70311,61514,35014,45514,78414,837
Interest expense2,6713,0912,2091,2381,2911,4491,5741,3161,2701,186
Pretax income7,5208,0231,05834,72924,3117,49717,68211,88512,3058,351
Income tax-266-28-1,1153,3281,8524771,384706-9,0491,123
Net income7,7718,0312,11931,37221,9799,61616,27311,15321,3087,215
YoY (Net income)-3.24%+279.00%-93.25%+42.74%+128.57%-40.91%+45.91%-47.66%+195.33%—
EPS (basic)1.371.420.385.593.921.732.921.903.571.18
EPS (diluted)1.361.410.375.473.851.712.871.873.521.17
YoY (EPS (diluted))-3.55%+281.08%-93.24%+42.08%+125.15%-40.42%+53.48%-46.88%+200.85%—
Diluted shares (weighted)5,7135,7005,7095,7335,7085,6325,6755,9776,0586,159

Balance sheet

Balance sheet. USD millions, except per-share figures (USD). Share counts in millions.
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023FY2022Dec 31, 2022FY2021Dec 31, 2021FY2020Dec 31, 2020FY2019Dec 31, 2019FY2018Dec 31, 2018FY2017Dec 31, 2017FY2016Dec 31, 2016
Cash & equivalents1,1421,0432,8534161,9441,7841,3051,1391,3422,595
Receivables11,87411,46311,17710,95211,4797,9308,7248,0258,2218,225
Inventory10,65410,85110,1898,9819,0598,0468,2837,5087,5786,783
Current assets42,89850,35843,33351,25959,69335,06732,80349,92641,14138,949
Goodwill71,26468,52767,78351,37549,20849,57758,65353,41155,95254,449
Intangible assets53,73155,41164,90043,37025,14628,47135,37035,21148,74152,648
Total assets208,160213,396226,501197,205181,476154,229167,489159,422171,797171,615
Current liabilities36,98442,99547,79442,13842,67125,92037,30431,85830,42731,115
Short-term debt2,9976,20010,2192,5601,6362,55815,3777,8769,6464,225
Long-term debt61,64157,40561,53832,88436,19537,13335,95532,90933,53831,398
Total liabilities121,385124,899137,213101,288104,01390,756104,04295,664100,141111,776
Retained earnings114,610116,725118,353125,656103,39496,77097,67089,55485,29171,774
Stockholders' equity86,47688,20389,01495,66177,20163,23863,14363,40771,30859,544
Shares outstanding5,6865,6675,6475,6195,6235,5785,5485,5525,9535,952

Cash flow

Cash flow. USD millions, except per-share figures (USD). Share counts in millions.
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023FY2022Dec 31, 2022FY2021Dec 31, 2021FY2020Dec 31, 2020FY2019Dec 31, 2019FY2018Dec 31, 2018FY2017Dec 31, 2017FY2016Dec 31, 2016
Operating cash flow11,70412,7448,70029,26732,58014,40312,58815,82716,47015,901
Capital expenditures2,6292,9093,9073,2362,7112,2522,1762,0421,9561,823
Free cash flow9,0759,8354,79326,03129,86912,15110,41213,78514,51414,078
YoY (Free cash flow)-7.73%+105.20%-81.59%-12.85%+145.82%+16.70%-24.47%-5.02%+3.10%—
Depreciation & amortization6,5927,0136,2905,0645,191—6,0106,3846,2695,757
Stock-based compensation7998775258721,182756718949840691
Share repurchases—002,000008,86512,1985,0005,000
Dividends per share1.721.691.651.611.571.531.461.381.281.20
Key financials (annual, 10-K)

Values as reported in each fiscal year's Form 10-K (XBRL data on SEC EDGAR); growth and ratios are computed from those values. Revenue is the total revenue figure the company tagged (omitted when the only figure tagged is evidently partial, e.g. below net income); growth is only shown between consecutive ~12-month fiscal years reported with the same revenue measure. Per-share figures and share counts are as reported and not adjusted for later stock splits. — = not reported.

FY2025 · per diluted weighted share

Per share and valuation context

EPS (diluted)
$1.36
Revenue per share
$10.95
FCF per share
$1.59
Book value per share
$15.14
Tangible book per share
-$6.74
Cash per share
$0.20
Dividends per share
$1.72
Public floatas of Jun 29, 2025
$138B

Price ratios need a live quote. This page shows no stock prices. Per-share figures are as reported, not adjusted for stock splits; comparisons across a likely split are left blank.

Price ratio calculator

Type a share price to compute ratios from the latest 10-K figures. Nothing is stored or sent. (FY2025)

Market capPrice × diluted weighted shares
—
P/EPrice ÷ diluted EPS
—
P/BPrice ÷ book value per share
—
P/SPrice ÷ revenue per share
—
P/FCFPrice ÷ FCF per share
—
Dividend yieldDividends per share ÷ price
—
SEC EDGAR

Filing timeline

  1. 8-KNew
    Current report· Oct 30, 2026(SEC EDGAR)
    • 5.02Officer or director changes
    • 9.01Financial statements and exhibits
  2. 10-QNew
    Quarterly report· Sep 27, 2026(SEC EDGAR)
  3. 8-KNew
    Current report· Nov 3, 2026(SEC EDGAR)
    • 2.02Results of operations
    • 9.01Financial statements and exhibits
  4. 10-Q
    Quarterly report· Jun 28, 2026(SEC EDGAR)
  5. 8-K
    Current report· Aug 4, 2026(SEC EDGAR)
    • 2.02Results of operations
    • 9.01Financial statements and exhibits
  6. 8-K
    Current report· Jun 18, 2026(SEC EDGAR)
    • 7.01Regulation FD disclosure
  7. 8-K
    Current report· Jun 18, 2026(SEC EDGAR)
    • 5.02Officer or director changes
    • 9.01Financial statements and exhibits
  8. 10-Q
    Quarterly report· Mar 29, 2026(SEC EDGAR)
  9. 8-K
    Current report· May 5, 2026(SEC EDGAR)
    • 2.02Results of operations
    • 9.01Financial statements and exhibits
  10. 8-K
    Current report· Apr 23, 2026(SEC EDGAR)
    • 5.07Shareholder vote results
All filings on SEC EDGAR
SIC 2834 · Pharmaceutical Preparations

Peers (same SIC code)

Peers (same SIC code)
TickerRevenue (FY)YoYNet marginROEF-Score5y revenue
JNJJOHNSON & JOHNSON$94.2B—28.5%———
LLYELI LILLY & Co$65.2B—31.7%———
MRKMerck & Co., Inc.$65B—28.1%———
PFEPFIZER INC (This company)$62.6Bdown 1.65%12.4%8.9%6/9
ABBVAbbVie Inc.$61.2B—6.9%———
ABTABBOTT LABORATORIES$44.3Bup 5.67%14.7%13.1%6/9
NVSNOVARTIS AG——————
AZNASTRAZENECA PLC——————
NVONOVO NORDISK A S——————
Peer median$65Bup 5.67%28.1%13.1%6/9—

Companies with the same 4-digit SIC code, ordered by latest revenue. The median excludes this company. — = not reported or not computable.

Frequently asked questions

What does PFIZER INC do?

The SEC classifies PFIZER INC under Standard Industrial Classification (SIC) code 2834, "Pharmaceutical Preparations". It is headquartered in New York, NY. It is incorporated in DE. In fiscal 2025 it reported revenue of $62.58B and net income of $7.77B in its annual 10-K report.

What was PFIZER INC's revenue in 2025?

PFIZER INC reported revenue of $62.58B for fiscal 2025, which ended Dec 31, 2025, down 1.6% from $63.63B in fiscal 2024, according to its annual 10-K report filed with the SEC on Feb 26, 2026.

What was PFIZER INC's net income in 2025?

PFIZER INC reported net income of $7.77B for fiscal 2025, a net margin of 12.4% of revenue.

Where is PFIZER INC listed?

According to the SEC, PFIZER INC's ticker PFE is listed on NYSE.

When does PFIZER INC's fiscal year end?

According to the SEC, PFIZER INC's fiscal year ends on December 31; its latest reported fiscal year (2025) ended Dec 31, 2025.

Source: SEC EDGAR · Last updated:

Ver en español

Not investment advice: This page shows financial data that companies reported to the US Securities and Exchange Commission, for information only. It is not investment advice or a recommendation to buy or sell any security, and it shows no stock prices. Data may be incomplete, restated or out of date — check the original filings on SEC EDGAR before making decisions.